Joshua Fitch is an editor for Contemporary Pediatrics.
Incorporating objective testing to add value to an ADHD diagnosis
Perry Roy, MD, explains how an FDA-cleared objective test can assist in an ADHD diagnosis.
FDA approves tovorafenib for most common form of childhood brain tumor
This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.
First radioactive drug approved for patients 12 years and up with SSTR-positive GEP-NETs
The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Ustekinumab biosimilar approved to treat moderate to severe plaque psoriasis
The biosimilar to ustekinumab is approved for patients 6 years and up, and is expected to be marketed on or after February 21, 2025.
Week in review: BLA accepted for meningococcal vaccine, single-tablet HIV regimen data
Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Managing and treating eating disorders
A discussion of outpatient management and treatment of eating disorders in youth patients, plus the importance of a multidisciplinary team throughout the process.
FDA accepts BLA for meningococcal ABCWY vaccine, target action date set
The 5-in-1 vaccine candidate has the potential to reduce shots and simplify the immunization process.
Substance use trends among youth and importance of screenings
A discussion regarding current substance use trends for youth in the United States.
Reducing elevated non-HDL-C levels in childhood could prevent premature cardiovascular disease
“These findings suggest that primordial and primary interventions to prevent and reduce elevated childhood non–HDL-C levels may help prevent premature CVD," wrote the study authors.
Bictegravir, emtricitabine, and tenofovir alafenamide efficacy, safety in children with HIV 2 years and up
The low-dose, coformulated regimen was well tolerated, and overall data supports its use in children with HIV aged 2 years and older weighing between 30.86 lbs (14 kg) and 55.11 lbs (25 kg).
RSV monoclonal antibody nirsevimab to be 5% more expensive
The monoclonal antibody was approved by the FDA on July 17, 2023 and quickly saw high demand at the onset of the RSV season.
Week in review: A new dermatology case study, and a new treatment for severe asthma
Patient-centered approach to updated AAP breastfeeding guidelines
Allison Scott, DNP, CPNP-PC, IBCLC, reviews the updated breastfeeding guidelines from the American Academy of Pediatrics.
Receptor targeting to identify medications for pediatric mental health concerns
Psychopharmacologic agents used in the pediatric population from the perspective of their interactions with receptor targets in the brain and body.
What the FDA approval of benralizumab means for children with severe asthma
Juanita Mora, MD, breaks down the FDA approval of benralizumab as an add-on maintenance therapy among patients with severe asthma aged 6 to 11 years.
Children younger than 5 years with HIV receiving ART have higher mortality than older persons
April 10, 2024 is National Youth HIV & AIDS Awareness Day.
Parents consider several factors when keeping a sick child home from school
When deciding whether to keep their child home from school, 4% of parents contacted a health care provider for advice.
Does vitamin C among pregnant smokers improve airway function trajectory in offspring?
"Our findings provide evidence for a direct association between maternal smoking during pregnancy and wheeze occurrence," wrote the authors.
FDA approves dolutegravir/lamivudine to treat HIV infection in adolescents
The treatment is approved for adolescents aged 12 years and older.
Week in review: New treatment for bacterial pneumonia, human trafficking awareness, and more
Incorporating PrEP and PEP into school-based health centers
Natasha Hoyte, MPH, CPNP-PC, explains how important PrEP and PEP in school health programs can be for youth, and the crucial role awareness plays.
Severe refractory status asthmaticus, research, and current trends
Lauren Flagg, DNP, APRN, CPNP-AC, discusses severe refractory status asthmaticus based on a session presented at the NAPNAP National Conference.
Children 4 months to 6 years lowest age group to receive COVID bivalent mRNA vaccine from federal group
Of the 600,238 bivalent vaccine doses administered by all providers in the study period, 35,114 (5.9%) were done so by FRPP partners.
Zevtera approved for community-acquired bacterial pneumonia in infants, adolescents, teens
The pediatric approval to treat CABP is 1 of 3 indications approved by the FDA.
DSMB recommends continuation of phase 3 trial evaluating central precocious puberty treatment
The single-arm study has an estimated enrollment of 93 participants, made up of females aged 2 to 8 years and males aged 2 to 9 years with CPP.
Inaxaplin to treat APOL1-mediated kidney disease moves to phase 3 trial
The phase 3 portion of the AMPLITUDE trial will include adolescents aged 10 to 17 years.
DMD candidate SGT-003 receives Rare Pediatric Disease Designation
The planned phase 1/2 INSPIRE Duchenne trial (NCT06138639) is a first in-human, open-label, multicenter trial to evaluate tolerability and safety of SGT-003.
Venous thromboembolism, heparin-induced thrombocytopenia, and direct oral anticoagulants
Chris Kyper, DNP, CPNP-AC/PC, breaks down characteristics of Heparin-induced thrombocytopenia, an uncommon adverse reaction to heparin.
Human trafficking awareness with Jessica Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
A discussion of human trafficking awareness and what primary care providers can do to spot red flags and implement evidence-based knowledge.
Week in review: FDA approvals and expanded indications
